Tubulin Inhibiting Agent Drug Class List

Drugs in Drug Class: Tubulin Inhibiting Agent

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mountain	GRISEOFULVIN, ULTRAMICROSIZE	griseofulvin, ultramicrosize	TABLET;ORAL	204371-001	Jan 9, 2014	AB	RX	No	No
Sandoz	GRISEOFULVIN, ULTRAMICROSIZE	griseofulvin, ultramicrosize	TABLET;ORAL	202805-001	Dec 26, 2018	AB	RX	No	No
Sandoz	GRISEOFULVIN, ULTRAMICROSIZE	griseofulvin, ultramicrosize	TABLET;ORAL	202805-002	Dec 26, 2018	AB	RX	No	No
Sigmapharm Labs Llc	GRISEOFULVIN,ULTRAMICROSIZE	griseofulvin, ultramicrosize	TABLET;ORAL	202545-001	Oct 22, 2012	AB	RX	No	No
Sigmapharm Labs Llc	GRISEOFULVIN,ULTRAMICROSIZE	griseofulvin, ultramicrosize	TABLET;ORAL	202545-002	Oct 22, 2012	AB	RX	No	No

Tubulin Inhibiting Agent Market Analysis and Financial Projection

The market for tubulin inhibitors in breast cancer treatment is experiencing dynamic growth driven by clinical advancements and shifting patent landscapes. These agents, which disrupt microtubule function to inhibit cancer cell division, remain critical in oncology therapeutics. Here's an in-depth analysis of current trends and developments:

Market Dynamics

1. Projected Growth and Regional Trends

   • The global tubulin inhibitors market for breast cancer was valued at $1.5 billion in 2022 and is projected to reach $3.2 billion by 2030, growing at a 10.5% CAGR[12]. Alternative estimates suggest a 6.3% CAGR through 2030, driven by rising breast cancer incidence and improved targeted therapies[5].
   • North America leads with 27.79% market share (2025), followed by Europe (23.18%) and Asia-Pacific (34.70%)[1]. Asia-Pacific, led by China and India, is growing fastest (5.1% CAGR) due to healthcare investments and increasing awareness[1][5].
   • Taxanes (e.g., paclitaxel, docetaxel) dominate the broader microtubule inhibitor market, accounting for 40% of global revenue due to their efficacy[6].

2. Key Drivers

   • Rising Breast Cancer Prevalence: Over 30% of new cancer cases in U.S. women are breast cancer, necessitating advanced therapies[12].
   • Innovative Drug Formulations: Liposomal and nanoparticle paclitaxel formulations reduce toxicity and improve efficacy[2][6].
   • Combination Therapies: Trials integrating tubulin inhibitors with immunotherapy or targeted agents enhance treatment outcomes[5][6].

3. Competitive Landscape

   • Major players include Bristol-Myers Squibb (paclitaxel), Genentech (Kadcyla), and Sanofi (Jevtana)[1][6].
   • Generics are gaining traction post-patent expirations (e.g., docetaxel), lowering costs but increasing competition[6][10].

Patent Landscape

1. Historical Focus and Recent Innovations

   • Early patents (pre-2013) prioritized colchicine-binding site inhibitors, emphasizing phenstatin and combretastatin derivatives[8][11]. Structural optimization for binding affinity and resistance mitigation was common.
   • Recent patents (e.g., Humanwell Healthcare, 2023) highlight dual-target inhibitors combining tubulin destabilization with kinase (Src) inhibition, addressing drug resistance and broadening therapeutic applications[9].

2. Pipeline and Clinical Trials

   • Over 70 tubulin inhibitors are in development, including novel agents like KX2-391 and HMN-214, which show potent tubulin polymerization inhibition[3][10].
   • Phase III trials focus on improving drug delivery (e.g., polymeric micelles) and expanding indications[2][6].

Challenges and Future Outlook

• Resistance Mechanisms: Persistent issues with tumor resistance drive research into next-gen scaffolds and biomarker-guided therapies[8][6].
• Cost and Competition: High R&D expenses and generic encroachment pressure pricing, though emerging markets offer growth opportunities[6][12].
• Personalized Medicine: Advances in genomics and combination regimens are expected to fuel a $6.8 billion microtubule inhibitor market by 2032[6].

---

"The emergence of dual-target inhibitors represents a paradigm shift in overcoming resistance and improving therapeutic windows." – Industry Expert, 2023[9]

Key Takeaways

• The Asia-Pacific region is pivotal for future market expansion.
• Dual-target inhibitors and novel formulations are reshaping the patent landscape.
• Generics and personalized therapies will balance affordability with innovation.

FAQs

1. Which companies lead the tubulin inhibitors market?
   Bristol-Myers Squibb, Genentech, and Sanofi dominate with taxane-based therapies.
2. What drives growth in developing regions?
   Increasing healthcare expenditure and rising breast cancer awareness.
3. How do dual-target inhibitors work?
   They block tubulin polymerization while inhibiting kinases like Src, enhancing anticancer effects.
4. What challenges do generics pose?
   They reduce prices but compel innovation in branded drug development.
5. What’s next for tubulin inhibitors?
   Focus on biomarker-driven therapies and nanoparticle delivery systems to improve precision.

References

1. https://www.cognitivemarketresearch.com/tubulin-inhibitors-for-breast-cancer-market-report
2. https://www.globenewswire.com/news-release/2018/02/15/1348926/0/en/Global-Cancer-Tubulin-Inhibitors-Market-Clinical-Trial-Insight-2024-Dosage-Price-Analysis-of-10-Commercialized-Drugs.html
3. https://www.mdpi.com/2218-273X/13/2/249
4. https://www.researchandmarkets.com/reports/4458874/global-cancer-tubulin-inhibitors-market-and
5. https://github.com/ajegiobitsa/Market-Research-Report-List-1/blob/main/tubulin-inhibitors-for-breast-cancer-market.md
6. https://datahorizzonresearch.com/microtubule-inhibitor-chemotherapy-drugs-market-7334
7. https://www.qyresearch.com/reports/4335003/tubulin-inhibitors-for-breast-cancer
8. https://www.benthamdirect.com/content/journals/pra/10.2174/15748928113089990042
9. https://www.bioworld.com/articles/699802-new-tubulin-src-dual-target-inhibitors-reported-in-humanwell-healthcare-patent
10. https://markets.businessinsider.com/news/stocks/global-cancer-tubulin-inhibitors-market-clinical-trial-insight-2024-dosage-price-analysis-of-10-commercialized-drugs-1015899859
11. https://hub.tmu.edu.tw/en/publications/tubulin-inhibitors-a-patent-survey
12. https://www.verifiedmarketreports.com/product/global-tubulin-inhibitors-for-breast-cancer-market-growth-status-and-outlook-2019-2024/